New stock news | Pi Xiang future submission Hong Kong Stock Exchange
According to the disclosure by the Hong Kong Stock Exchange on June 10, Bairong Future Group has submitted an application to be listed on the main board of the Hong Kong Stock Exchange, with Industrial and Commercial Bank International and Shenwan Hongyuan (Hong Kong) acting as its joint sponsors.
According to the disclosure by the Hong Kong Stock Exchange on June 10th, Pai Xiang Future Group (referred to as Pai Xiang Future) has submitted an application to the Hong Kong Stock Exchange main board, with CICC International, Shenwan Hongyuan Group (Hong Kong) as its joint sponsors. The prospectus shows that Pai Xiang Future is an independent distributed cloud computing service provider. According to data from Zero Intelligence Consulting, as of December 31, 2025, the company operates the largest computing power network in China in terms of computing nodes, and based on revenue in 2025, it is the largest independent edge cloud computing service provider in China. Based on the average daily token consumption in 2025, the company also ranks first among independent AI cloud computing service providers in China.
Related Articles

William Li: Chinese car companies are transitioning from single-point competition to system competition.

New stock news | Meedu once again submits application to the Hong Kong Stock Exchange to develop and provide comprehensive technology-driven marketing, sales, and operational support services.

New Stock News | Lanna Cheng submits again to the Hong Kong Stock Exchange, dedicated to the discovery, development, and commercialization of radiopharmaceuticals for cancer diagnosis and treatment.
William Li: Chinese car companies are transitioning from single-point competition to system competition.

New stock news | Meedu once again submits application to the Hong Kong Stock Exchange to develop and provide comprehensive technology-driven marketing, sales, and operational support services.

New Stock News | Lanna Cheng submits again to the Hong Kong Stock Exchange, dedicated to the discovery, development, and commercialization of radiopharmaceuticals for cancer diagnosis and treatment.

RECOMMEND





